Ann: Appendix 4D and Half Year Financial Report, page-2

certainly chewing through the $'s. external R&D???
revenue on other products still quite low given the period that has elapsed since their introduction - notwithstanding that it has increased 50-80% (as we are talking about a very low base).
if they don't obtain FDA approval in the short term then could be looking at CR within 12 months.

need FDA approval and decent marketing agreements to occur - if revenue to be on the same trajectory as current products then there will be cash issues in the next 12 months - but hopefully that is sorted.